<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374321</url>
  </required_header>
  <id_info>
    <org_study_id>TRO40303CLEQ1491-1</org_study_id>
    <nct_id>NCT01374321</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction</brief_title>
  <official_title>Phase II, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of the phase 2 prospective, multicenter, randomized, double-blind,&#xD;
      placebo-controlled study is to assess safety and efficacy of TRO40303 administered just&#xD;
      before balloon inflation during percutaneous coronary intervention (PCI) for limitation of&#xD;
      infarct size in patients treated for acute myocardial infarction (AMI).&#xD;
&#xD;
      The study is being conducted in 9 centres in Sweden, Denmark, Norway and France. One hundred&#xD;
      eighty patients will be included. It will last one month per patient and its overall duration&#xD;
      will be 11 months.&#xD;
&#xD;
      The efficacy will be assessed by infarct size expressed as area under the curve for creatine&#xD;
      kinase and troponin I (blood sampling at D1, D2 and D3), and also evaluated by Cardiac&#xD;
      Magnetic Resonance.&#xD;
&#xD;
      Safety will be assessed by&#xD;
&#xD;
        -  clinic evaluation,&#xD;
&#xD;
        -  blood samples (hematology, biochemistry, renal and hepatic function),&#xD;
&#xD;
        -  Recording and follow-up of major adverse events occurring during the first 48h after&#xD;
           reperfusion (death, heart failure, AMI, stroke, recurrent ischemia, the need for repeat&#xD;
           revascularization, renal or hepatic, vascular complication and bleeding).&#xD;
&#xD;
        -  ECG&#xD;
&#xD;
        -  Recording cardiac events during one month after AMI&#xD;
&#xD;
        -  Follow-up of global left ventricular function by Echocardiography at D3 and D30.&#xD;
&#xD;
      Demographic and medical history at inclusion and non-cardiac events occurring during the&#xD;
      first 30 days will be recorded. TRO40303 plasma concentration will be assessed at 15 min, 6h,&#xD;
      and 12h post the end of administration.&#xD;
&#xD;
      Sample size calculation assuming a reduction of 35% of the AUC for Troponin I release, for a&#xD;
      statistical power of 85% and a probability of type I error of 0.05.&#xD;
&#xD;
      Main analysis: between-group comparisons of AUCs for serum troponin I and CK release will be&#xD;
      performed using O'Brien's method for multiple endpoints testing.&#xD;
&#xD;
      Secondary analysis: comparisons of the CMR criteria described above will be performed using&#xD;
      mixed model of ANCOVA.&#xD;
&#xD;
      All analyses will be performed on the Full Analysis Set and Per protocol populations.&#xD;
&#xD;
      Safety analysis: A comparison of the incidence of cumulative adverse clinical events between&#xD;
      the groups will be performed by Fisher's exact tests.&#xD;
&#xD;
      Subjects will undergo primary PCI and receive concomitant medications according to current&#xD;
      standard of care.&#xD;
&#xD;
      After coronary angiography is performed but just before balloon inflation is performed,&#xD;
      patients who meet the enrollment criteria will be randomly assigned to either the control&#xD;
      group or the TRO40303 group. Randomization is ensured by taking the treatment units in&#xD;
      ascending and consecutive order in each strata (anterior/posterior as determined on ECG).&#xD;
      Just before balloon inflation, ideally less than 5 minutes, and with a maximum of 15 minutes&#xD;
      before balloon inflation and stenting, the patients in the TRO40303 group will receive an&#xD;
      intravenous slow-bolus (35 mL/min) injection of 6 mg/kg of TRO40303 injected in peripheral&#xD;
      IV. The patients in the control group will receive an equivalent volume of the placebo.&#xD;
      Patients will be hospitalized for as long as there is a medical indication. CMR and&#xD;
      echocardiography will accordingly be conducted as in/out patient between day 3 (ideally) and&#xD;
      5. A follow-up visit will be conducted one month after PCI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size expressed as area under the curve for Creatine kinase and Troponin I</measure>
    <time_frame>Blood samples will be collected at admission and every 6 hours until 72h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size evaluated by Cardiac Magnetic Resonance</measure>
    <time_frame>A cardiac magnetic resonance between day 3 and Day 5 after balloon inflation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Acute Myocardial Infarctus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRO40303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRO40303</intervention_name>
    <description>6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)</description>
    <arm_group_label>TRO40303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and Female with non childbearing potential patients&#xD;
&#xD;
          2. Age &gt; 18 years old&#xD;
&#xD;
          3. First acute myocardial infarction&#xD;
&#xD;
          4. Occlusion should affect the following coronary arteries: LAD,or the dominant or&#xD;
             balanced RCA, or the dominant or balanced LCx&#xD;
&#xD;
          5. Acute myocardial infarction defined as&#xD;
&#xD;
               -  nitrate resistant chest pain ≥ 30 min&#xD;
&#xD;
               -  ST elevation: New ST elevation at the J-point in two contiguous leads with the&#xD;
                  cut-off points: ≥ 2 mV in men or ≥ 0.15 mV in women in leads V2-V3 and/or ≥ O.1&#xD;
                  mV in other leads&#xD;
&#xD;
          6. Presenting within 6h of onset of chest pain&#xD;
&#xD;
          7. Clinical decision to treat with percutaneous coronary intervention&#xD;
&#xD;
          8. Occlusion of culprit artery with a Thrombolysis In Myocardial Infarction (TIMI) flow&#xD;
             grade 0-1 at time of admission and before percutaneous coronary intervention&#xD;
&#xD;
          9. Have signed an Informed Consent to participate to the trial before any study related&#xD;
             procedure has been taken&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac arrest, ventricular fibrillation, cardiogenic shock, stent thrombosis,&#xD;
             previous AMI, angina within 48h before admission, previous CABG, treatment with&#xD;
             intravenous fibrinolytic therapy within the 72 hours to PCI&#xD;
&#xD;
          2. Atrial fibrillation (could confound CMR analysis)&#xD;
&#xD;
          3. Pace-maker&#xD;
&#xD;
          4. Concurrent inflammatory, infectious or malignant disease&#xD;
&#xD;
          5. Biliary obstruction or hepatic insufficiency at the time of inclusion in the study&#xD;
&#xD;
          6. Be possibly dependent on the Investigator or the Sponsor (eg including but not limited&#xD;
             to affiliated employee)&#xD;
&#xD;
          7. Participated in any other investigational drug or therapy study with a non-approved&#xD;
             medication, within the previous 3 months&#xD;
&#xD;
          8. Patient under guardianship&#xD;
&#xD;
          9. History of egg allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Atar, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>NO-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>4956</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larsen</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

